Related references
Note: Only part of the references are listed.Cell-Based Identification of New IDO1 Modulator Chemotypes
Elisabeth Hennes et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
The emerging roles of IDO2 in cancer and its potential as a therapeutic target
Pengcheng Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme
Matthew M. Hamilton et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease
Xiang-Li Ning et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Unique Sulfur-Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors
Yi-Hui Peng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors
Wieslaw M. Kazmierski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
Mingxing Hu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Silencing IDO2 in dendritic cells: A novel strategy to strengthen cancer immunotherapy in a murine lung cancer model
Yanling Liu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2020)
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool
Martina Mandarano et al.
FRONTIERS IN IMMUNOLOGY (2020)
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
Alexander J. Muller et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
Indoleamine 2,3-dioxygenase 2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma
Wakana Yamasuge et al.
CANCER SCIENCE (2019)
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
Qian Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
Todd A. Triplett et al.
NATURE BIOTECHNOLOGY (2018)
The Role of indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
Lilla Hornyak et al.
FRONTIERS IN IMMUNOLOGY (2018)
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Asha Nayak-Kapoor et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indo1-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate
Stefano Crosignani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (ID01) Inhibitor for Immunooncology
Eddy W. Yue et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
The 1,2,3-triazole ring as a bioisostere in medicinal chemistry
Elisa Bonandi et al.
DRUG DISCOVERY TODAY (2017)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Jason D. Fontenot et al.
JOURNAL OF IMMUNOLOGY (2017)
1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2)
Ute F. Rohrig et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD plus and inhibits in vivo tumor growth
Yanling Liu et al.
ONCOTARGET (2016)
Tryptophan-degrading enzymes in tumoral immune resistance
Nicolas van Baren et al.
FRONTIERS IN IMMUNOLOGY (2015)
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
George C. Prendergast et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
The SOCS3-Independent Expression of IDO2 Supports the Homeostatic Generation of T Regulatory Cells by Human Dendritic Cells
Sara Trabanelli et al.
JOURNAL OF IMMUNOLOGY (2014)
Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
Young-Kwan Lee et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2014)
Synthesis of Novel Estrogen Receptor Antagonists Using Metal-Catalyzed Coupling Reactions and Characterization of Their Biological Activity
Xiang-Rong Jiang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases
G. C. Prendergast et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Studies on Tissue and Cellular Distribution of Indoleamine 2,3-Dioxygenase 2: The Absence of IDO1 Upregulates IDO2 Expression in the Epididymis
Masakazu Fukunaga et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2012)
Application of a Sequential Multicomponent Assembly Process/Huisgen Cycloaddition Strategy to the Preparation of Libraries of 1,2,3-Triazole-Fused 1,4-Benzodiazepines
James R. Donald et al.
ACS COMBINATORIAL SCIENCE (2012)
Tryptophan metabolism, from nutrition to potential therapeutic applications
Nathalie Le Floc'h et al.
AMINO ACIDS (2011)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan
Hajime J. Yuasa et al.
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY (2010)
Functional and phenotypic effects of AhR activation in inflammatory dendritic cells
Jaishree Bankoti et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2010)
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
Stefan Loeb et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model
Eddy W. Yue et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Stefan Loeb et al.
NATURE REVIEWS CANCER (2009)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
DH Munn et al.
IMMUNITY (2005)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
JD Fontenot et al.
NATURE IMMUNOLOGY (2003)
Share Paper
